Vivus's obesity drug Qnexa exceeds expectations in Phase III
This article was originally published in Scrip
Executive Summary
Vivus's obesity drug Qnexa (topiramate and phentermine) has met the primary endpoint of two Phase III studies, EQUIP and CONQUER, demonstrating a significant weight loss compared with placebo.